Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

Abstract Background It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the ef...

Full description

Bibliographic Details
Main Authors: Yuri Komaki, Yoshinori Ozono, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Mitsue Sueta, Tadashi Miike, Shojiro Yamamoto, Hirofumi Uto, Kazunori Kusumoto, Toshimasa Ochiai, Junya Kato, Naoto Komada, Kazuo Kuroki, Toshiharu Eto, Masafumi Shigehira, Shuichi Hirono, Kenji Nagata, Hiroshi Kawakami
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Gastroenterology
Subjects:
Chronic hepatitis C
Direct-acting antivirals
Glecaprevir
Pibrentasvir
Sustained virological response
Online Access:https://doi.org/10.1186/s12876-022-02284-z

Internet

https://doi.org/10.1186/s12876-022-02284-z

Similar Items